Unverified50% confidenceBenchmarkExact time
In a prospective HPK1 study, DrugHarness achieved more favorable median docking scores than Biomni among system-specific candidate molecules.
1
Sources
50%
Confidence
Medium-term (~90 days)
Relevance
10/19/2026
First Seen
Valid until: 1/17/2027
Sources
Related Entities
Related Claims
UnverifiedA synthetic compound designed by DrugHarness achieved a cellular IC50 of 14.19 nM, a 2.64-fold potency improvement over the best input reference molecule, with activity comparable to selected compounds designed by two senior medicinal chemists.59% similarUnverifiedHPK1 (hematopoietic progenitor kinase 1) is a negative regulator of the T-cell receptor signaling pathway, and inhibiting HPK1 can enhance anti-tumor immune responses, making it a hot target in immuno-oncology.56% similar
Cite This Claim
Stable URI
https://kongchang.com/claim/1065883API
curl https://kongchang.com/api/v1/knowledge/claims/1065883MCP
get_claim(id=1065883)